We are live on ! Find out more
LPCN icon

Lipocine
LPCN

47 hedge funds and large institutions have $24.9M invested in Lipocine in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 2

90% more capital invested

Capital invested by funds: $13.1M → $24.9M (+$11.8M)

81% more funds holding

Funds holding: 26 → 47 (+21)

13.36% more ownership

Funds ownership: 29.36% → 42.72% (+13%)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

Holders
47
Holders Change
+21
Holders Change %
+80.77%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
9
Reduced
10
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
IC
Ikarian Capital
Texas
+$2.69M
2
EP
Eversept Partners
New York
+$2.57M
3
RA
Rosalind Advisors
Ontario, Canada
+$1.93M
4
ACM
AIGH Capital Management
Maryland
+$1.74M
5
SC
Stempoint Capital
New York
+$1.4M

Top Sellers

1
DP
Diadema Partners
New Jersey
-$1.84M
2
SCM
Squadron Capital Management
Illinois
-$697K
3
PAP
Persistent Asset Partners
Hong Kong
-$498K
4
Ameriprise
Ameriprise
Minnesota
-$40.6K
5
UBS Group
UBS Group
Switzerland
-$18.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
XT
26
XTX Topco
Cayman Islands
$143K +$156K +17,923 New
PAP
27
Persistent Asset Partners
Hong Kong
$107K -$498K -57,134 -81%
Northern Trust
28
Northern Trust
Illinois
$104K -$1.03K -118 -0.9%
PCM
29
Prelude Capital Management
New York
$101K +$110K +12,630 New
Ameriprise
30
Ameriprise
Minnesota
$91.5K -$40.6K -4,656 -29%
Barclays
31
Barclays
United Kingdom
$75.2K +$82K +9,412 New
UBS Group
32
UBS Group
Switzerland
$27.9K -$18.4K -2,109 -38%
Wells Fargo
33
Wells Fargo
California
$21.6K +$23.6K +2,706 New
VGA
34
Vanguard Global Advisers
Pennsylvania
$13.5K +$14.7K +1,691 New
TRCT
35
Tower Research Capital (TRC)
New York
$7.46K +$8.13K +933 New
Fidelity Investments
36
Fidelity Investments
Massachusetts
$5K +$4.78K +549 +713%
Morgan Stanley
37
Morgan Stanley
New York
$4.59K -$1.54K -177 -24%
CSC
38
Caldwell Sutter Capital
California
$3.76K – – –
JP Morgan Chase
39
JP Morgan Chase
New York
$2.97K +$3.42K +392 New
Osaic Holdings
40
Osaic Holdings
Arizona
$1.14K +$218 +25 +21%
Group One Trading
41
Group One Trading
Illinois
$1.05K -$261 -30 -19%
PF
42
PlanVest Financial
Maryland
$887 +$967 +111 New
SS
43
SBI Securities
Japan
$535 – – –
T
44
Tidemark
California
$471 – – –
BWL
45
Bogart Wealth LLC
Virginia
$24 +$26 +3 New
FFA
46
Farther Finance Advisors
California
$9 +$9 +1 New
HWM
47
HighMark Wealth Management
Minnesota
– -$803 -100 Closed
Bank of America
48
Bank of America
North Carolina
– -$417 -52 Closed
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
– -$200 -23 -32%
1
2

LPCN Hedge Fund Activity: Q1 2026 in Review

47 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2026, worth a combined $24.9M — up 90% from $13.1M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new LPCN positions and 2 closed out — a net gain of 22 holders — while 9 added to existing stakes and 10 trimmed.

The largest buyer was Ikarian Capital, adding an estimated $2.69M. The largest seller was Diadema Partners, cutting an estimated $1.84M.

  • 47 institutional investors held Lipocine (LPCN) as of Q1 2026, up from 26 in Q4 2025.
  • Funds reported $24.9M of Lipocine stock for Q1 2026, up 90% quarter-over-quarter.
  • 24 funds opened new Lipocine positions in Q1 2026 and 2 closed out, a net change of +22 holders.
  • The largest Lipocine buyer in Q1 2026 was Ikarian Capital, an estimated $2.69M added.
  • The largest Lipocine seller in Q1 2026 was Diadema Partners, an estimated $1.84M sold.

Based on aggregated 13F filings for Q1 2026.